Sonendo, Inc. Reports First Quarter 2023 Financial Results
May 10, 2023 LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter ended March 31, 2023. Recent Highlights Total revenue of $10.7 million for the first quarter of 2023, representing growth of 19%, compared to prior year period Procedure instrument […]
Masimo Reports First Quarter 2023 Financial Results
May 10, 2023 IRVINE, Calif.–(BUSINESS WIRE)–Masimo (Nasdaq: MASI) today announced its financial results for the first quarter of 2023, ended April 1, 2023. First Quarter 2023 Financial Results Consolidated revenue was $565.0 million, representing 85.7% reported growth compared to $304.2 million in the first quarter of 2022. Healthcare revenue was $346.7 million, which represents 14.0% […]
Evolus Reports First Quarter 2023 Results and Provides Business Update
May 10, 2023 NEWPORT BEACH, Calif.–(BUSINESS WIRE)—- $EOLS–Evolus, Inc. reports financial results for the first quarter ended March 31, 2023 and provides a business update. Go to Source Author:
Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
May 10, 2023 NEWPORT BEACH, Calif.–(BUSINESS WIRE)—- $EOLS–Evolus, Inc. announces it has entered into a definitive agreement to be the exclusive U.S. distributor of a line of five unique dermal fillers. Go to Source Author:
Sensydia raises $8M round to advance breakthrough CPS cardiac assessment platform
May 9, 2023 LOS ANGELES–(BUSINESS WIRE)–Non-invasive cardiac assessment company Sensydia today announced it has raised approximately $8M in new funding from an expanded syndicate of investors. Proceeds of the financing will enable the company to prepare for commercialization of its groundbreaking non-invasive cardiac assessment platform, Cardiac Performance System (CPS™). Sensydia continues to push the boundaries […]
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
May 9, 2023 THOUSAND OAKS, Calif.–(BUSINESS WIRE)—- $ATRA #CART–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2023, recent business highlights and key upcoming catalysts. “We […]
Xencor Reports First Quarter 2023 Financial Results
May 9, 2023 PASADENA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights. “In the first quarter, we and […]
Applied BioCode Announces Distribution Agreement with Medline Industries
May 8, 2023 SANTA FE SPRINGS, Calif.–(BUSINESS WIRE)–Applied BioCode today announced an agreement with Medline Industries, a leading manufacturer and distributor of healthcare products, to distribute the MDx-3000 System and its comprehensive menu. The MDx-3000 menu consists of products that enable the diagnosis of upper respiratory infections and gastrointestinal infections, as well as a suite […]
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2023 LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology reported the grant of inducement restricted stock unit awards to 3 new employees, as required by Nasdaq Listing Rule 5635(c)(4). Go to Source Author:
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
May 6, 2023 ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application […]